✦ LIBER ✦

Perioperative Anti-Tumor Necrosis Factor Therapy Does Not Increase the Rate of Early Postoperative Complications in Crohn’s Disease

✍ Scribed by Basil S. Nasir; Eric J. Dozois; Robert R. Cima; John H. Pemberton; Bruce G. Wolff; William J. Sandborn; Edward V. Loftus; David W. Larson

Book ID: 107412012
Publisher: Springer-Verlag
Year: 2010
Tongue: English
Weight: 188 KB
Volume: 14
Category: Article
ISSN: 1091-255X
DOI: 10.1007/s11605-010-1341-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Perioperative Treatment with Infliximab

Perioperative Treatment with Infliximab in Patients with Crohn’s Disease and Ulcerative Colitis is Not Associated with an Increased Rate of Postoperative Complications

✍ Hiroko Kunitake; Richard Hodin; Paul C. Shellito; Bruce E. Sands; Joshua Korzeni 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 161 KB

The Disease Activity Score is not suitab

The Disease Activity Score is not suitable as the sole criterion for initiation and evaluation of anti–tumor necrosis factor therapy in the clinic: Discordance between assessment measures and limitations in questionnaire use for regulatory purposes

✍ Frederick Wolfe; Kaleb Michaud; Theodore Pincus; Daniel Furst; Edward Keystone 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB 👁 2 views

## Abstract ## Objective The Disease Activity Score (DAS) is widely used in clinical trials. A DAS of 5.1 defines the level of severe rheumatoid arthritis (RA) and is the criterion for the initiation of anti–tumor necrosis factor therapy in the UK and The Netherlands. In North America, similar rul